triple negative breast cancer Archives -

Market Access/ News/ News

NICE says no to Keytruda in triple-negative breast cancer

Phil Taylor HEOR, immuno-oncology, Keytruda, Merck & Co, NHS, NICE, Oncology, triple negative breast cancer 0 Comment

There isn’t enough evidence to support the use of Merck & Co/MSD’s Keytruda in combination with chemotherapy as

NICE says no to Keytruda in triple-negative breast cancer

https://pharmaphorum.com/news/nice-says-no-to-keytruda-in-triple-negative-breast-cancer/

News/ News/ Oncology

AZ, Daiichi take aim at Gilead in triple-negative breast cancer

Phil Taylor antibody-drug conjugate, AstraZeneca, Daiichi Sankyo, datopotamab deruxtecan, Gilead Sciences, Oncology, triple negative breast cancer, Trodelvy 0 Comment

AstraZeneca and Daiichi Sankyo have reported new data with their antibody-drug conjugate for triple-negative breast cancer (TNBC), as

AZ, Daiichi take aim at Gilead in triple-negative breast cancer

https://pharmaphorum.com/news/az-daiichi-take-aim-at-gilead-in-triple-negative-breast-cancer/

News/ News/ Oncology

Gilead moves closer to Chinese filing for Trodelvy in TNBC

Phil Taylor China, Everest Medicines, Gilead Sciences, Oncology, triple negative breast cancer, Trodelvy 0 Comment

Gilead Sciences’ Trodelvy has met its objectives in a phase 2b trial in triple-negative breast cancer (TNBC) carried

Gilead moves closer to Chinese filing for Trodelvy in TNBC

https://pharmaphorum.com/news/gilead-moves-closer-to-chinese-filing-for-trodelvy-in-tnbc/

News/ News/ Oncology

Gilead tags Merck for first-line triple negative breast cancer trial

Phil Taylor Gilead Sciences, immuno-oncology, Keytruda, Merck & Co, Oncology, triple negative breast cancer, Trodelvy 0 Comment

Take two recently-approved immunotherapies for triple negative breast cancer (TNBC), put them together, and what do you get?

Gilead tags Merck for first-line triple negative breast cancer trial

https://pharmaphorum.com/news/gilead-tags-merck-for-first-line-triple-negative-breast-cancer-trial/

News/ News/ Oncology

Merck gets EU approval for Keytruda in triple-negative breast cancer

Phil Taylor immuno-oncology, Keytruda, Merck & Co, Oncology, regulatory approval, Roche, Tecentriq, triple negative breast cancer 0 Comment

Merck & Co has claimed EU approval for Keytruda in triple-negative breast cancer (TNBC), a particularly hard-to-treat form

Merck gets EU approval for Keytruda in triple-negative breast cancer

https://pharmaphorum.com/news/merck-gets-eu-approval-for-keytruda-in-triple-negative-breast-cancer/

News/ News/ Oncology

After false start, Merck claims Keytruda approval in early breast cancer

Phil Taylor fda, immuno-oncology, Keytruda, Merck & Co, Oncology, regulatory approval, triple negative breast cancer 0 Comment

Merck & Co’s Keytruda has just picked up its 30th approval from the FDA, and it is a

After false start, Merck claims Keytruda approval in early breast cancer

https://pharmaphorum.com/news/after-false-start-merck-claims-keytruda-approval-in-early-breast-cancer/

NICE’s track record in cancer drugs: the impact of the CDF and the role of interim funding

News/ News/ Oncology

AZ/Daiichi unveil data from TNBC hopeful datopotamab deruxtecan

Richard Staines breast cancer, cancer, triple negative breast cancer 0 Comment

AstraZeneca and Daiichi Sankyo have revealed new data from datopotamab deruxtecan in triple negative breast cancer (TNBC) –

AZ/Daiichi unveil data from TNBC hopeful datopotamab deruxtecan

https://pharmaphorum.com/news/az-daiichi-unveil-data-from-tnbc-hopeful-datopotamab-deruxtecan/

Boehringer Ingelheim, Biberach, Germany, February 2007

News/ News/ Oncology

Boehringer buys NBE for €1.18bn, adding cancer ADC expertise

Phil Taylor antibody-drug conjugate, Boehringer Ingelheim, M&A, NBE-Therapeutics, Oncology, triple negative breast cancer 0 Comment

Boehringer Ingelheim has expanded its oncology focus for the second time this week by buying Swiss biotech NBE-Therapeutics,

Boehringer buys NBE for €1.18bn, adding cancer ADC expertise

https://pharmaphorum.com/news/boehringer-buys-nbe-for-e1-18bn-adding-cancer-adc-expertise/

News/ News/ Oncology

Immunomedics wows ESMO with breast cancer data reveal

Richard Staines breast cancer, ESMO, Gilead, Immunomedics, Roche, triple negative breast cancer 0 Comment

Immunomedics has revealed the trial data that convinced Gilead to stage a $21 billion takeover, after the biotech’s

Immunomedics wows ESMO with breast cancer data reveal

https://pharmaphorum.com/news/immunomedics-wows-esmo-with-breast-cancer-data-reveal/

Trending

triple negative breast cancer

Login